Skip to main content
. 2019 Dec 18;12(1):1688616. doi: 10.1080/19420862.2019.1688616

Figure 8.

Figure 8.

Model predictions using validated PBPK-PD model to simultaneously evaluate the effect of (1) CAR-T dose and (2) Initial tumor burden on (A and D) tumor growth inhibition (TGI), (B and E) generation of ‘number of CAR-Target complexes per tumor cell’ in the tumor extravascular space and (D and F) CAR-T cell expansion in blood: 1) CAR-T dose: Simulations were performed after single IV administration of anti-BCMA (bb2121) CAR-T cells in RPMI-8226 bearing xenografts, at dose-levels of 0.1, 1, 5, 10 and 50 million CAR-T cells per mouse. (2) Initial Tumor Burden: Simulations were performed after single IV administration of anti-BCMA (bb2121) CAR-T cells at dose-level of 5 million CAR-T cells per mouse in RPMI-8226 bearing xenografts with initial tumor burdens of 50, 100, 150, 250, 500 and 1000 mm3.